Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study

L. G. Lum, A. Thakur, C. Pray, N. Kouttab, Mehrdad Abedi, A. Deol, W. M. Colaiace, R. Rathore

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

A pilot phase I clinical trial involving 15 infusions of anti-CD3 × anti-CD20 bispecific Ab (CD20Bi)-armed anti-CD3-activated T cells (aATC) and low-dose IL-2 was conducted in three non-Hodgkin's lymphoma (NHL) patients (two high-risk and one refractory) after autologous SCT. The feasibility of T-cell expansion, safety of aATC infusions, cytotoxic immune responses and trafficking of aATC were evaluated. Three NHL patients received 15 infusions of 5 × 10 9 aATC (three infusions/week for 3 weeks and one infusion/week for 6 weeks) between days 1 and 65 after SCT with IL-2. There were no dose-limiting toxicities. Chills, fever, hypotension and malaise were the common side effects. Engraftment was delayed in one patient with a low stem cell dose. CD20Bi aATC infusions induced specific cytotoxicity directed at lymphoma targets. Endogenous peripheral blood mononuclear cells from two patients mediated anti-lymphoma cytotoxicity above preSCT background (P<0.001). 111 In labeled aATC trafficked to the lungs at 1 h and accumulated in the liver and bone marrow after 24 h. aATC infusions given over 69 days in combination with IL-2 were safe, did not inhibit engraftment, and induced endogenous cytotoxic responses directed at lymphoma targets.

Original languageEnglish (US)
Pages (from-to)73-79
Number of pages7
JournalBone Marrow Transplantation
Volume49
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Non-Hodgkin's Lymphoma
Interleukin-2
T-Lymphocytes
Lymphoma
Chills
Clinical Trials, Phase I
Hypotension
Blood Cells
Fever
Stem Cells
Bone Marrow
Safety
Lung
Liver

Keywords

  • Activated T-cells
  • Autologous SCT
  • Bispecific antibody
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma : A pilot study. / Lum, L. G.; Thakur, A.; Pray, C.; Kouttab, N.; Abedi, Mehrdad; Deol, A.; Colaiace, W. M.; Rathore, R.

In: Bone Marrow Transplantation, Vol. 49, No. 1, 2014, p. 73-79.

Research output: Contribution to journalArticle

Lum, L. G. ; Thakur, A. ; Pray, C. ; Kouttab, N. ; Abedi, Mehrdad ; Deol, A. ; Colaiace, W. M. ; Rathore, R. / Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma : A pilot study. In: Bone Marrow Transplantation. 2014 ; Vol. 49, No. 1. pp. 73-79.
@article{294194b41bbe4540b4e57ce25652f338,
title = "Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study",
abstract = "A pilot phase I clinical trial involving 15 infusions of anti-CD3 × anti-CD20 bispecific Ab (CD20Bi)-armed anti-CD3-activated T cells (aATC) and low-dose IL-2 was conducted in three non-Hodgkin's lymphoma (NHL) patients (two high-risk and one refractory) after autologous SCT. The feasibility of T-cell expansion, safety of aATC infusions, cytotoxic immune responses and trafficking of aATC were evaluated. Three NHL patients received 15 infusions of 5 × 10 9 aATC (three infusions/week for 3 weeks and one infusion/week for 6 weeks) between days 1 and 65 after SCT with IL-2. There were no dose-limiting toxicities. Chills, fever, hypotension and malaise were the common side effects. Engraftment was delayed in one patient with a low stem cell dose. CD20Bi aATC infusions induced specific cytotoxicity directed at lymphoma targets. Endogenous peripheral blood mononuclear cells from two patients mediated anti-lymphoma cytotoxicity above preSCT background (P<0.001). 111 In labeled aATC trafficked to the lungs at 1 h and accumulated in the liver and bone marrow after 24 h. aATC infusions given over 69 days in combination with IL-2 were safe, did not inhibit engraftment, and induced endogenous cytotoxic responses directed at lymphoma targets.",
keywords = "Activated T-cells, Autologous SCT, Bispecific antibody, Non-Hodgkin's lymphoma",
author = "Lum, {L. G.} and A. Thakur and C. Pray and N. Kouttab and Mehrdad Abedi and A. Deol and Colaiace, {W. M.} and R. Rathore",
year = "2014",
doi = "10.1038/bmt.2013.133",
language = "English (US)",
volume = "49",
pages = "73--79",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma

T2 - A pilot study

AU - Lum, L. G.

AU - Thakur, A.

AU - Pray, C.

AU - Kouttab, N.

AU - Abedi, Mehrdad

AU - Deol, A.

AU - Colaiace, W. M.

AU - Rathore, R.

PY - 2014

Y1 - 2014

N2 - A pilot phase I clinical trial involving 15 infusions of anti-CD3 × anti-CD20 bispecific Ab (CD20Bi)-armed anti-CD3-activated T cells (aATC) and low-dose IL-2 was conducted in three non-Hodgkin's lymphoma (NHL) patients (two high-risk and one refractory) after autologous SCT. The feasibility of T-cell expansion, safety of aATC infusions, cytotoxic immune responses and trafficking of aATC were evaluated. Three NHL patients received 15 infusions of 5 × 10 9 aATC (three infusions/week for 3 weeks and one infusion/week for 6 weeks) between days 1 and 65 after SCT with IL-2. There were no dose-limiting toxicities. Chills, fever, hypotension and malaise were the common side effects. Engraftment was delayed in one patient with a low stem cell dose. CD20Bi aATC infusions induced specific cytotoxicity directed at lymphoma targets. Endogenous peripheral blood mononuclear cells from two patients mediated anti-lymphoma cytotoxicity above preSCT background (P<0.001). 111 In labeled aATC trafficked to the lungs at 1 h and accumulated in the liver and bone marrow after 24 h. aATC infusions given over 69 days in combination with IL-2 were safe, did not inhibit engraftment, and induced endogenous cytotoxic responses directed at lymphoma targets.

AB - A pilot phase I clinical trial involving 15 infusions of anti-CD3 × anti-CD20 bispecific Ab (CD20Bi)-armed anti-CD3-activated T cells (aATC) and low-dose IL-2 was conducted in three non-Hodgkin's lymphoma (NHL) patients (two high-risk and one refractory) after autologous SCT. The feasibility of T-cell expansion, safety of aATC infusions, cytotoxic immune responses and trafficking of aATC were evaluated. Three NHL patients received 15 infusions of 5 × 10 9 aATC (three infusions/week for 3 weeks and one infusion/week for 6 weeks) between days 1 and 65 after SCT with IL-2. There were no dose-limiting toxicities. Chills, fever, hypotension and malaise were the common side effects. Engraftment was delayed in one patient with a low stem cell dose. CD20Bi aATC infusions induced specific cytotoxicity directed at lymphoma targets. Endogenous peripheral blood mononuclear cells from two patients mediated anti-lymphoma cytotoxicity above preSCT background (P<0.001). 111 In labeled aATC trafficked to the lungs at 1 h and accumulated in the liver and bone marrow after 24 h. aATC infusions given over 69 days in combination with IL-2 were safe, did not inhibit engraftment, and induced endogenous cytotoxic responses directed at lymphoma targets.

KW - Activated T-cells

KW - Autologous SCT

KW - Bispecific antibody

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84891888501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891888501&partnerID=8YFLogxK

U2 - 10.1038/bmt.2013.133

DO - 10.1038/bmt.2013.133

M3 - Article

C2 - 24056738

AN - SCOPUS:84891888501

VL - 49

SP - 73

EP - 79

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -